GlassScriptPhysician profile
William Henry Hickling
NPI 1659337624
$3,717.57
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,169 · 2020: $979 · 2021: $918 · 2022: $637 · 2023: $14.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $890.89 | 2019-2023 | Briviact |
| Supernus Pharmaceuticals, INC. | $463.09 | 2019-2022 | |
| Greenwich Biosciences, INC. | $388.67 | 2019-2021 | |
| Aquestive Therapeutics, INC. | $385.39 | 2019-2022 | |
| Neurelis, INC. | $310.63 | 2020-2022 | |
| Eisai INC. | $206.38 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $199.14 | 2019-2021 | |
| Philips North America LLC | $95.54 | 2019-2022 | |
| Livanova USA, INC. | $85.58 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $76.50 | 2019 | |
| Upsher-Smith Laboratories LLC | $75.89 | 2019 | |
| Novartis Pharmaceuticals Corporation | $73.40 | 2019 | |
| Jazz Pharmaceuticals INC. | $56.61 | 2022 | |
| Aprecia Pharmaceuticals, LLC | $54.69 | 2020-2022 | |
| Sarepta Therapeutics, INC. | $47.43 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $46.44 | 2021-2022 | |
| Tris Pharma INC | $41.94 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $33.22 | 2019 | |
| Sk Life Science, INC. | $29.30 | 2020-2021 | |
| Biocodex, INC. | $27.38 | 2019 | |
| Biomarin Pharmaceutical INC. | $26.72 | 2020-2022 | |
| Amgen INC. | $24.00 | 2020 | |
| Grifols USA, LLC | $18.72 | 2021 | |
| Corium, LLC | $17.38 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.12 | 2019 | |
| Zogenix INC. | $13.22 | 2021 | |
| Azurity Pharmaceuticals, INC. | $12.64 | 2022 | |
| Travere Therapeutics, INC. | $1.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hickling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.